CA2631773C - Composition and use of phyto-percolate for treatment of disease - Google Patents

Composition and use of phyto-percolate for treatment of disease Download PDF

Info

Publication number
CA2631773C
CA2631773C CA2631773A CA2631773A CA2631773C CA 2631773 C CA2631773 C CA 2631773C CA 2631773 A CA2631773 A CA 2631773A CA 2631773 A CA2631773 A CA 2631773A CA 2631773 C CA2631773 C CA 2631773C
Authority
CA
Canada
Prior art keywords
percolate
phyto
disease
patient
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2631773A
Other languages
English (en)
French (fr)
Other versions
CA2631773A1 (en
Inventor
Tiffany Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivo Bioscience Inc
Original Assignee
Zivo Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zivo Bioscience Inc filed Critical Zivo Bioscience Inc
Publication of CA2631773A1 publication Critical patent/CA2631773A1/en
Application granted granted Critical
Publication of CA2631773C publication Critical patent/CA2631773C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2631773A 2005-12-02 2006-12-04 Composition and use of phyto-percolate for treatment of disease Active CA2631773C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74177405P 2005-12-02 2005-12-02
US60/741,774 2005-12-02
PCT/US2006/046320 WO2007065024A2 (en) 2005-12-02 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Publications (2)

Publication Number Publication Date
CA2631773A1 CA2631773A1 (en) 2007-06-07
CA2631773C true CA2631773C (en) 2022-04-26

Family

ID=38092904

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2631773A Active CA2631773C (en) 2005-12-02 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Country Status (5)

Country Link
EP (1) EP1954800A4 (enExample)
JP (1) JP2009518312A (enExample)
AU (1) AU2006320264A1 (enExample)
CA (1) CA2631773C (enExample)
WO (1) WO2007065024A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117122A1 (en) * 2009-11-16 2011-05-19 Tiffany Thomas COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-kB
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
CA2625818A1 (en) 2005-04-20 2006-10-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
US20160051526A1 (en) * 2013-04-09 2016-02-25 Cresset Biomolecular Discovery Ltd The Local Treatment of Inflammatory Ophthalmic Disorders
WO2014201372A1 (en) 2013-06-13 2014-12-18 Health Enhancement Products, Inc. Compounds and methods for affecting cytokines
ES2972377T3 (es) 2015-02-16 2024-06-12 Zivo Bioscience Inc Composiciones antinflamatorias e inmunomoduladoras que comprenden Klebsormidium y usos de las mismas
US11806375B2 (en) 2016-02-16 2023-11-07 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307213B1 (en) * 2000-08-10 2004-04-28 Ocean Nutrition Canada Ltd. Chlorella preparations exhibiting immunomodulating properties
WO2005112987A2 (en) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Method of preparation and use of fibrinolytic enzymes in the treatment of disease

Also Published As

Publication number Publication date
JP2009518312A (ja) 2009-05-07
EP1954800A2 (en) 2008-08-13
WO2007065024A2 (en) 2007-06-07
EP1954800A4 (en) 2010-03-03
AU2006320264A1 (en) 2007-06-07
WO2007065024A3 (en) 2008-01-10
CA2631773A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
US8791060B2 (en) Composition and use of phyto-percolate for treatment of disease
Ekesiobi et al. Hyping the Inhibitory Activity of Xylopia aethiopica against Vibrio cholerae using Azithromycin
JP2025060946A (ja) 免疫機能を調節するため及び腸の炎症を治療するためのベータ－１，３－グルカンの使用
Im et al. Immunomodulatory activity of polysaccharides isolated from Salicornia herbacea
de Alencar Alves et al. Antihyperglycemic and antioxidant activities of a lectin from the marine red algae, Bryothamnion seaforthii, in rats with streptozotocin-induced diabetes
TWI667036B (zh) 植物萃取物於調控ｐｄｇｆｃ、ｆｇｆ２、ｉｇｆ１ｒ、ｐｔｇｉｓ、ｎｏｓ３、ｅｄｎ１、ｐｌａｔ、ｐｒｏｃ、ｖｗｆ、ｆ３、ｓｅｒｐｉｎｅ１、ｉｌ－８、ｉｃａｍ１、ｖｃａｍ１及ｃａｓｐ８基因的用途
US20130251698A1 (en) Composition and method for affecting cytokines and nf-kb
US10166270B2 (en) Composition and method for affecting cytokines and NF-κB
CA2631773A1 (en) Composition and use of phyto-percolate for treatment of disease
US20080031863A1 (en) Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease
JP2016502983A (ja) 硫酸化ポリアニオン性多糖及び非硫酸化ポリアニオン性多糖を含む藻類抽出物及びその使用
US8586053B2 (en) Composition and use of phyto-percolate for treatment of disease
Fan et al. Pyroptosis the emerging link between gut microbiota and multiple sclerosis
EP1928247A2 (en) Composition and use of phyto-percolate for treatment of disease
WO2016053142A1 (ru) Композиция для детоксикации организма
Tu et al. Protective role of bayberry extract: associations with gut microbiota modulation and key metabolites
RU2426552C2 (ru) Экстракты phaseolus vulgaris, их применение и композиции, содержащие их
Jia et al. The potential auxiliary effects of Sargassum fusiform polysaccharides on sitagliptin in the treatment of diabetes mellitus
AU2010305251A1 (en) Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin B12 and Vitamin B6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing
AU2013204257A1 (en) Composition and use of phyto-percolate for treatment of disease
CN107073032A (zh) 肾衰竭发展抑制剂、肾衰竭预防剂及硫酸吲哚酚产生抑制剂
TW201619390A (zh) 一種製備具有抗凝血活性的海藻寡糖的方法
Al-Jowari Comparative investigation of amoxicillin and cephalexin administration on some biochemical parameters in male rabbits
Wang et al. Ulva polysaccharide alleviates Parkinson's disease by regulating inflammation, oxidative damage, and gut microbiota
RU2432957C2 (ru) Способ получения средства, обладающего гастрозащитной активностью

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241202

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241202

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251201

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251201